SEC Form 4 · accession 0001209191-18-063787
BELLICUM PHARMACEUTICALS, INC · BLCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Atabak Mokari
Officer — Sr. VP and CFO
Period of report
Dec 19, 2018
Accepted (ET)
Dec 20, 2018 · 9:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358403
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.42 | Dec 19, 2018 | A | 300,000 | A | — | Dec 18, 2028 | Common Stock | 300,000 | 300,000 | D |
Explanation of responses
- F125% of the shares subject to the stock option vest and become exercisable on December 19, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.